| Literature DB >> 32603428 |
Sonoko Sakata1, Miyuki Tsumura1, Tadashi Matsubayashi2, Shuhei Karakawa1, Shunsuke Kimura1, Moe Tamaura1, Tsubasa Okano3, Takuya Naruto3, Yoko Mizoguchi1, Reiko Kagawa1, Shiho Nishimura1, Kohsuke Imai3, Tom Le Voyer4,5, Jean-Laurent Casanova4,5,6,7,8,9, Jacinta Bustamante4,5,8,10, Tomohiro Morio3, Osamu Ohara11, Masao Kobayashi1, Satoshi Okada1.
Abstract
Autosomal recessive (AR) complete signal transducer and activator of transcription 1 (STAT1) deficiency is an extremely rare primary immunodeficiency that causes life-threatening mycobacterial and viral infections. Only seven patients from five unrelated families with this disorder have been so far reported. All causal STAT1 mutations reported are exonic and homozygous. We studied a patient with susceptibility to mycobacteria and virus infections, resulting in identification of AR complete STAT1 deficiency due to compound heterozygous mutations, both located in introns: c.128+2 T>G and c.542-8 A>G. Both mutations were the first intronic STAT1 mutations to cause AR complete STAT1 deficiency. Targeted RNA-seq documented the impairment of STAT1 mRNA expression and contributed to the identification of the intronic mutations. The patient's cells showed a lack of STAT1 expression and phosphorylation, and severe impairment of the cellular response to IFN-γ and IFN-α. The case reflects the importance of accurate clinical diagnosis and precise evaluation, to include intronic mutations, in the comprehensive genomic study when the patient lacks molecular pathogenesis. In conclusion, AR complete STAT1 deficiency can be caused by compound heterozygous and intronic mutations. Targeted RNA-seq-based systemic gene expression assay may help to increase diagnostic yield in inconclusive cases after comprehensive genomic study. © The Japanese Society for Immunology. 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.Entities:
Keywords: mycobacteria; primary immunodeficiency; target RNA sequence; virus
Year: 2020 PMID: 32603428 DOI: 10.1093/intimm/dxaa043
Source DB: PubMed Journal: Int Immunol ISSN: 0953-8178 Impact factor: 4.823